The archive label '(Z)-alpha-Santalal analogue' refers to an unresolved sandalwood-like sesquiterpene aldehyde signal reported in Buddha Wood GC/MS data rather than to a fully identity-locked reference standard. Live evidence is therefore narrow but still usable: current sources support its repeated analytical occurrence in authentic Eremophila mitchellii oil and its relationship to a broader wood-oil profile rich in eremophilane sesquiterpenes, while direct constituent-specific pharmacology, toxicology, and regulatory data were not located. This record should be treated as a chemistry-and-identity placeholder with transparent ambiguity, not as a well-characterized standalone active.
Chemical identity and composition
A current REVIVE / Essential Oil University GC/MS report for authentic Buddha Wood lists '(Z)-alpha-Santalal analogue' at 3.75%, and an earlier 2023 chromatogram for the same lot label reports the same unnamed peak at the same percentage. The wording 'analogue' and 'unknown santalol analog' indicate the analyst considered the signal related to alpha-santalal-type chemistry without claiming a definitive structure assignment. A PubChem record exists for alpha-Santalal itself as a sesquiterpene aldehyde, but this file does not equate the archive constituent with that fully identified compound.
Aroma and practical use
- Use the recorded woody, soft, dry, sandalwood-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
repeat gc ms occurrence in buddha wood
Two public Essential Oil University / REVIVE Buddha Wood reports list the same unresolved peak as a santalal-like analogue at 3.75%, which supports the archive constituent as a reproducible analytical marker even though the exact structure remains unresolved.
Measured: repeat peak assignment and relative abundance
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
oil level bioactivity context
A 2011 Phytochemistry paper reported that Eremophila mitchellii wood oil is dominated by biologically active eremophilanes and that all tested oils and purified eremophilanes showed cytotoxicity in vitro, which is useful oil-level context but not evidence that the unresolved santalal analogue peak itself drives the effect.
Measured: cytotoxicity of oils and purified eremophilanes
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific safety dossier, IFRA limit, dermal study, or phototoxicity review was verified for the unresolved '(Z)-alpha-Santalal analogue' peak.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the exact structure is not publicly resolved in the reviewed sources, safety assumptions should not be imported directly from alpha-Santalal or other sandalwood aldehydes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- The exact structure behind the analyst label '(Z)-alpha-Santalal analogue' was not resolved in a public primary source during this pass.
- No standalone pharmacology or toxicology literature for the exact unresolved analogue peak was located.
- Any mechanistic claims stronger than repeated occurrence in Buddha Wood oil would be speculative with the current evidence.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.